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AbstrAct
Epidermal growth factor receptor (EGFR) is an important mediator of tumor cell 
survival and proliferation. The detection of EGFR mutations can predict prognoses 
and indicate when treatment with EGFR tyrosine kinase inhibitors should be used. As 
such, the development of highly sensitive methods for detecting EGFR mutations is 
important. Targeted next-generation sequencing is an effective method for diagnosing 
mutations. We compared the abilities of enrichment PCR followed by ultra-deep 
pyrosequencing (UDP), UDP alone, and PNA-mediated RT-PCR clamping to detect low-
frequency EGFR mutations in tumor cell lines and tissue samples. Using enrichment 
PCR-UDP, we were able to detect the E19del and L858R mutations at minimum 
frequencies of 0.01% and 0.05%, respectively, in the PC-9 and H197 tumor cell lines. 
We also confirmed the sensitivity of detecting the E19del mutation by performing a 
titration analysis in FFPE tumor samples. The lowest mutation frequency detected 
was 0.0692% in tissue samples. EGFR mutations with frequencies as low as 0.01% 
were detected using enrichment PCR-UDP, suggesting that this method is a valuable 
tool for detecting rare mutations, especially in scarce tissue samples or those with 
small quantities of DNA.
INtrODUctION
Epidermal growth factor receptor (EGFR) is a 
critical mediator of tumor cell survival and proliferation 
[1]. EGFR is overexpressed in 43-89% of non–small-
cell lung carcinoma (NSCLC) cells and has become an 
important therapeutic target for the treatment of lung 
cancer [2-5]. Mutations in this gene can predict prognoses 
and indicate the optimal timing for treatment with EGFR 
tyrosine kinase inhibitors (TKIs) [6, 7]. Therefore, the 
development of sensitive and specific methods for the 
detection of EGFR mutations would be valuable. Recent 
studies have attempted to develop such methods using 
Sanger sequencing, pyrosequencing, and specific real-
time polymerase chain reaction (PCR) [4, 8, 9]. Although 
Sanger sequencing is considered as the gold standard 
for the detection mutations, this approach is limited by 
its low sensitivity and its requirement that mutant alleles 
exist at frequencies of at least 15-20% [10]. Ultra-
deep pyrosequencing (UDP) overcomes some of these 
limitations by enabling amplification of the target DNA 
through PCR and by its capability to perform much longer 
reads than other techniques. In fact, this method often 
produces more than 10,000 reads per sequencing reaction 
[11, 12]. Despite the advantages that UDP technology 
offers over Sanger sequencing and PCR-based methods, 
UDP is still limited by its low sensitivity when screening 
for rare mutations [13-16]. Many efforts have been made 
to identify low-frequency genetic mutations that appear in 
approximately 2-5% of tumor cells using UDP technology 
[13, 17].
In this study, we compared three methods, namely 
peptide nucleic acid (PNA)–mediated PCR clamping, 
UDP, and enrichment PCR-UDP, to develop a more 
sensitive method for the detection of EGFR mutations. 
Here, we report that enrichment PCR-UDP can detect 
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EGFR mutations with frequencies as low as 0.01% in 
heterogeneous samples. Our results can be used to assist 
in the identification of EGFR mutations in rare or difficult-
to-obtain tissue samples.
rEsULts
comparison of enrichment Pcr-UDP, UDP, and 
PNA-mediated rt-Pcr clamping
We selected two lung cancer cell lines that exhibit 
mutations in EGFR to confirm the respective sensitivities 
of the UDP and enrichment PCR-UDP methods, namely 
PC-9 cells, which possess a deletion in exon 19 (E19del), 
and H197 cells, which contain a substitution mutation 
(L858R) in exon 21. Titration analysis using a mixture of 
HeLa and EGFR mutant cells was performed to evaluate 
the lower limit of detection for each method. The samples 
evaluated consisted of mixed populations of 100% (no 
HeLa cells), 10%, 1%, 0.5%, 0.1%, 0.05%, and 0.01% 
mutant cells (with either E19del or L858R), as well as 
HeLa cells alone. We analyzed serially diluted genomic 
DNA to obtain mutation/wild-type DNA proportions of 0, 
0.01, 0.05, 0.1, 0.5, 1, 10, and 100%. Using enrichment 
PCR-UDP (Figure 1), we were able to detect the E19del 
and L858R mutations at minimum frequencies of 0.01 and 
0.05%, respectively. However, the minimum frequency 
detected by UDP was only 0.5% (Figure 2). Thus, 
enrichment PCR-UDP was more sensitive than UDP in 
detecting low-frequency EGFR mutations.
Next, we tested whether enrichment PCR-UDP and 
UDP can detect rare EGFR mutations within the same 
FFPE tumor tissues, and correlated these results with those 
obtained in the same tissues by PNA-mediated real-time 
PCR clamping. Enrichment PCR-UDP detected 90.35% 
variation for E19del in FFPE sample 1 with a higher 
resolution, whereas UDP detected 1.73% variation for 
E19del in the same sample. Moreover, the resolution of the 
variation ratio of L858R in samples 7 and 8 was increased 
in enrichment PCR-UDP (25.29-99.29% and 3.8-88.83% 
in FFPE samples 7 and 8, respectively (Table 1). To assess 
the possibility of false-positive or false-negative results, 
we screened the FFPE samples for both mutations using 
PNA-mediated real-time PCR clamping. These results 
were identical to those from enrichment PCR-UDP, 
indicating the lack of false-positive or false-negative 
results from the enrichment PCR-UDP approach. Tables 
S1 and S2 summarize the number of passed reads, total 
length of the sequencing data, and average read length at 
each base across all runs for the sequencing library pools 
and the barcoded amplicon runs.
Confirmation of the sensitivity of detection in 
FFPE samples
We confirmed the sensitivity of E19del detection by 
performing a titration analysis on FFPE sample 1. Sample 
DNA was serially diluted to produce mutation frequencies 
of 1.73, 0.346, 0.0692, and 0.01384%. Using enrichment 
PCR-UDP, the lowest mutation frequency detected was 
0.0692%. In contrast, the lowest mutation frequency 
detected by the UDP method was 1.73% (Figure 3). Thus, 
we confirmed that enrichment PCR-UDP is more sensitive 
than UDP for the detection of EGFR mutations in FFPE 
samples.
DIscUssION
New methods for the detection of low-frequency 
mutations in heterogeneous samples are needed to 
improve diagnostic accuracy and, ultimately, patient 
prognosis. In this study, we evaluated the use of the newly 
developed enrichment PCR-UDP method in enhancing 
the detection of mutations via parallel pyrosequencing 
with the Roche 454 Junior system (Figure 1). We 
found that PCR enrichment combined with UDP could 
detect lower-frequency EGFR mutations than UDP 
alone. The copy number of mutated sequences was 
magnified by PCR enrichment before next generation 
sequencing (NGS)-based amplicon resequencing, which 
enabled a clear distinction between actual mutations 
and background sequencing noise. Combining blocker-
PCR technology with UDP improved the detection limit 
of targeted amplicon resequencing of low-abundance 
mutations. Enrichment PCR-UDP is advantageous due to 
its high sensitivity in detecting mutant alleles and single 
nucleotide polymorphism variants. Moreover, we selected 
PNAs for use as a blocker with UDP because these 
molecules form a polyamide skeleton that is not affected 
by salt concentration and maintains a stable bond [18]. 
The thermal stability of PNA binding to complementary 
nucleic acids is higher than that of DNA and RNA. 
Because they are not substrates for DNA polymerases, 
PNA oligomers suppress the amplification of wild-type 
sequences confined by pairs of DNA oligonucleotide 
primers in PNA-mediated enrichment PCR [19]. 
In this study, we compared three methods for the 
detection of EGFR mutations, namely PNA-mediated 
PCR clamping, UDP, and enrichment PCR-UDP. Both 
UDP alone and enrichment-based UDP methods utilize 
the same PCR primer pairs that contain barcodes, 
sequencing adaptors, and the PCR premix. The only 
major difference is whether or not wild-type blocker 
(PNA probe) is incorporated. These advances are 
derived from mutant-specific amplification methods 
that make use of a polymerase elongation arrest strategy 
[20]. Competitive clamping was more effective than 
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Figure 1: Schematic diagram of the enrichment PCR-UDP workflow. Step I. Mutant Enrichment PCR. Step I. The wildtype-
specific blocker suppresses amplification of the wildtype allele, which enables enrichment of the mutant allele. PCR amplification is 
conducted on the wildtype specific blocker (PNA probe, red). The blocking probe preferentially hybridizes to wildtype alleles and 
inhibits their amplification at the extension temperature (68°C), resulting in enrichment of mutant PCR fragments. Step II. Ultra-Deep 
Pyrosequencing (UDP): Sequencing library preparation PCR was performed using enrichment PCR products as a target and adaptor and 
barcode-conjugated primer pairs. PCR amplicons are analyzed by UDP as follows: sequencing library preparation PCR  library of single-
stranded DNA fragments  one DNA molecule per bead  clonal amplification of DNA in emulsion  beads deposited into wells  
independent sequencing of each bead [29]. Step III. Data Analysis: Variations can be detected by changing the number of sequence reads 
compared against a reference [22]. Pol, polymerase; APS, adenosine phosphosulfate; PPi, pyrophosphate; ATP, adenosine triphosphate
Oncotarget13745www.impactjournals.com/oncotarget
Figure 2: comparison of enrichment Pcr-UDP and UDP for detection of E19del and L858r EGFR mutations. A. The 
horizontal axis indicates the ratio of EGFR mutation based on genomic DNA from PC-9 (left) and H1975 (right) cells mixed with HeLa cell 
genomic DNA. The vertical axis shows the observed variation results by enrichment UDP. b. A variation plot analysis of E19del. EGFR 
exon 19 deletions are in-frame deletions that occur within exon 19. c. A variation plot analysis of L858R (T>G). The L858R mutation 
results in a leucine to arginine substitution at position 858 of EGFR [27]. B and C, light gray: deletion; dark gray: point mutation. 
Figure 3: The sensitivity of mutation detection by UDP and enrichment PCR-UDP in FFPE samples. The horizontal axis 
shows the expected value of the fraction of EGFR E19del mutants in the FFPE sample. The vertical axis shows the observed variation 
results of EGFR E19del mutants by UDP and enrichment PCR-UDP.
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elongation arrest. However, compared to competitive 
clamping, clamping by elongation arrest offers greater 
flexibility in the choice of target sites for PNA oligomers 
and primers. This flexibility facilitates NGS sequencing 
panel design with mutant-enriched sequencing results. 
In the competition method, primer design is restricted 
by position and temperature. Moreover, the primers must 
avoid other possible mutations, making it more difficult 
to use in NGS systems. A PNA clamping-based method 
uses “competition of primer and PNA probe” for mutant-
specific PCR. In our approach, we are taking advantage of 
the benefits associated with the “elongation arrest method” 
and “blocking of polymerase extension”. 
Enrichment PCR-UDP technology is integrated NGS 
technology that is based on UDP but incorporates PNA 
blocking to increase the sensitivity of mutation detection. 
After mutation-specific PCR amplification, samples 
are prepared for NGS analysis by removing nonspecific 
amplification products. Recent studies reported the 
development of various technologies, including targeted 
NGS, PNA-mediated PCR clamping, and allele-specific 
PCR, that enable greater sensitivity for the detection 
of minor mutant alleles with low frequencies [21-23]. 
Moreover, various technologies have been developed and 
tested for the detection of EGFR mutations. DeBiase et al. 
compared UDP with Sanger sequencing and demonstrated 
that Sanger sequencing was incapable of detecting 
mutations below 40%, whereas NGS detected a proportion 
of neoplastic cells as low as 5% [24]. Bellevicine et al. 
reported an immunocytochemistry-based method using 
mutant-specific anti-EGFR antibodies that detected 10% 
mutation [25]. Comparison of the amplification refractory 
mutation system (ARMS) with Sanger sequencing by 
Shaozhang et al. revealed that ARMS (94.4%) was 
more sensitive than Sanger sequencing (72.2%) for the 
detection of EGFR mutations in patients with NSCLC 
[26]. However, the lack of a recognized standard method 
renders the evaluation of these technologies difficult. We 
also tested EGFR mutations using a PNA-mediated PCR 
clamping method to determine the frequency of EGFR 
mutations in heterogeneous samples. This highly sensitive 
method has been demonstrated to detect EGFR mutations 
in the presence of background signals that are 100 to 1,000 
times more abundant [23, 27]. Our results showed that 
enrichment PCR-UDP produces results similar to PNA-
mediated real-time PCR clamping for the detection of 
EGFR mutations. Therefore, enrichment PCR-UDP is a 
sensitive method that can be used to detect rare mutations, 
and is a viable alternative to PNA-mediated real-time PCR 
clamping (allele-specific real-time PCRs). 
Although FFPE tissue samples can offer significant 
patient information, the quantity and quality of the tissue 
contained within them are often inadequate for detecting 
rare mutant alleles. Hence, highly sensitive methods 
are required to detect mutant alleles in FFPE samples. 
We demonstrated the performance of enrichment PCR-
UDP in the detection of rare EGFR mutations in FFPE 
samples. In addition, we established and validated its 
use in the detection of E19del and L858R mutations in 
FFPE samples, which contain small amounts of DNA. 
In fact, our sensitivity analysis demonstrated that up to 
5 ng of DNA was available for analysis from each of our 
tissue samples, and that enrichment UDP can detect low-
frequency genetic mutations (<0.05%).
Enrichment PCR-UDP is a powerful method for 
NGS that, when combined with ongoing advances in the 
detection and quantitation of EGFR mutations, will help 
to better identify patients with NSCLC, who are most 
likely to derive the greatest benefit from treatment with 
EGFR TKIs. Drug-sensitive EGFR mutations are reported 
in 10-30% of patients with NSCLC [28]. Thus, detection 
of genetic changes in EGFR is critical for improving 
diagnosis and developing targeted therapies. Enrichment 
PCR-UDP can target any region of interest with a high 
level of sensitivity and specificity easily and rapidly. 
Therefore, this novel technology may become one of 
the most practical and useful methods for the detection 
of EGFR mutations in NSCLC patients. Moreover, 
this approach will aid in the development of additional 
technologies for the detection of rare EGFR mutations in 
clinical trials.
MAtErIALs AND MEtHODs
Preparation of genomic DNA targets
Genomic DNA from PC-9 cells, which harbor 
a E19del deletion in exon 19, and H1975 cells, which 
possess an L858R mutation in exon 21 of EGFR, were 
serially diluted to the ratios of 0, 0.01, 0.05, 0.1, 0.5, 1, 10, 
and 100% with HeLa cell genomic DNA (New England 
Biolabs, Beverly, MA, USA) to a final concentration 
of 15 ng/µL. Genomic DNA was extracted from cells 
using the High Pure PCR Template Preparation Kit 
(Roche Diagnostics, Mannheim, Germany) according 
to the manufacturer’s instructions. The manufactured 
DNA targets were stored at -20°C until use. The clinical 
formalin-fixed paraffin-embedded (FFPE) tumor 
samples were obtained from Yonsei Medical University 
Hospital. This study was approved by the Hospital Ethics 
Committee.
PNA-mediated EGFr real-time Pcr clamping
The EGFR real-time PCR clamping mutation kit 
(Panagene Inc., Daejeon, Korea) was used according 
to the manufacturer’s instructions. Real-time PCR was 
performed with a real-time PCR system (CFX 96, Bio-
Rad, Hercules, CA, USA) using 15 ng of genomic DNA. 
The data for each mutation were interpreted according to 
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the kit manual after curve analysis and calculation of ∆Ct 
values.
PCR amplification for conventional next-
generation sequencing
The target samples were analyzed by next-
generation sequencing (NGS) for EGFR mutations with 
the Cancer Panel on a GS Junior Sequencer (Roche 
Diagnostics). For conventional 454-targeted resequencing, 
30 ng of genomic DNA was used in the PCR of the EGFR 
panel (SeaSun Biomaterials, Daejeon, Korea). Subsequent 
processing of the samples was performed according to the 
manufacturer’s protocol.
Enrichment Pcr for mutant-enriched NGs and 
sequencing library preparation
To increase the resolution of low-level somatic 
mutant molecules within a high background of wildtype 
molecules, the InsightTM Onco Panel for EGFR (SeaSun 
Biomaterials) was used for mutant enrichment PCR 
according to the manufacturer’s instructions. This assay 
was performed using 30 ng of genomic DNA, and 
subsequent processing of the samples was performed 
according to the manufacturer’s protocol. PCR samples 
contained non-specific PCR products that mainly included 
primer dimers, which make NGS sequencing difficult 
due to their short read lengths. These non-specific PCR 
products were removed by AgencourtAMPure XP beads 
(Beckman Coulter, Vienna, Austria) using a 1:1 DNA-
to-bead ratio. Sequencing library preparation PCR was 
performed using 2 μL of purified PCR product from 
enrichment PCR amplification as a template, EGFR 
Insight 2x Seq Lib Pep Premix (SeaSun Biomaterials), 
and each barcoded primer pair. The sequencing adaptor 
with a multiplex identifier was conjugated using the 
manufacturer’s protocol. Any unwanted short fragments 
were removed with AgencourtAMPure XP beads 
(Beckman Coulter) using a 1:1 DNA-to-bead ratio.
Quantitation and normalization of sequencing 
amplicons
The purified amplicons were quantitated by Pico-
Green (Life Technologies, Carlsbad, CA, USA) utilizing 
an external Infinite F200Pro fluorometer (Tecan, Grodig, 
Austria) with Magellan v7.0 Software (Tecan). Based 
on the standard concentrations, the signals were directly 
converted to ng/μL, and the coefficient of determination 
(validation criteria, r2 > 0.99) was calculated from eight 
DNA standards ranging from 0 to 100 ng/μL. For emulsion 
PCR amplification, the concentrations of the amplicons 
were converted to molecules per μL using the associated 
amplicon length. The manufactured DNA pools were 
stored at –20°C until further use.
Ultra-deep pyrosequencing
Pyrosequencing of the amplicons was performed 
according to the manufacturer’s protocol using the GS 
Junior System (Roche Diagnostics). Emulsion PCR, 
breaking, and bead enrichment were conducted using the 
GS Junior Titanium emPCR Kit, Lib-L emPCR Reagents, 
Lib-L Kit, Oil and Breaking Kit, and the Bead Recovery 
Reagents Kit according to the supplier’s instructions 
(Roche Diagnostics). For emulsion PCR, we used a copy-
per-bead ratio of 0.5. Enrichment of the DNA-carrying 
magnetic beads was accomplished using a magnetic 
particle collector (Invitrogen, Life Technologies). The 
quantity of the enriched beads was determined with the 
GS Junior Bead Counter (Roche Diagnostics). Finally, we 
loaded 100,000 to 500,000 beads onto the PicoTiterPlate 
(Roche Diagnostics). Sequencing was carried out 
according to standard Roche/454 protocols using the GS 
Titanium Sequencing Kit (Roche Diagnostics) and the GS 
Junior device.
Data analysis
Processed and quality-filtered reads were analyzed 
and the sequencing data were visualized using the GS 
Amplicon Variant Analyzer (Roche Diagnostics). Target 
amplicons (excluding adaptors and multiplex identifiers) 
were used as references to align the amplicon reads. The 
template-specific portions of the fusion primers were 
considered as primer A and primer B, and the known 
mutations in the selected samples were defined as 
substitutions relative to the reference sequence.
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